seborrheic dermatitis
Conditions
Interventions
Test Group:Experimental Group Intervention - Investigational Drug Pulian Qingjie Granules (also known as Qingre Jiedu Granules) Experimental Group Intervention - Drug Specification 20g/bag, 20g*10 bag
Cotrol Group:Control Group Intervention - Control Drug Selenium Sulfide Lotion Control Group Intervention - Drug Specification 100ml/bottle (Informed Consent Form), 150g/bottle (Protocol) Control Grou
excipients include titanium dioxide, glycerin, bentonite, etc. Control Group Intervention - Manufacturer Janssen Pharmaceutica (Xi'an) Co., Ltd. (Informed Consent Form), Jiangsu Disanuo Pharmaceutical
Sponsors
Shanghai Skin Disease Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Outpatients with mild to moderate scalp seborrheic dermatitis who meet the Western medical diagnostic criteria and the Traditional Chinese Medicine (TCM) syndrome differentiation of lung heat syndrome 2. Aged 18-65 years, regardless of gender 3. No systemic use of corticosteroids within 2 weeks before treatment; topical corticosteroids or oral antihistamines discontinued for more than 1 week 4. Good compliance, willingness to take medication as per the treatment plan during the study period, and avoid taking other drugs that may affect the efficacy 5. Voluntarily participate in the study, sign the informed consent form, and agree to strictly follow the study protocol
Exclusion criteria
Exclusion criteria: 1. Patients who do not meet the Western medical diagnostic criteria or TCM syndrome type 2. Women who are pregnant, planning to become pregnant or breastfeeding; men of childbearing age planning to have children 3. Patients with severe primary diseases such as cardiovascular, kidney, lung, liver diseases; endocrine system diseases; malignant tumors; mental and neurological disorders; hematological/hematopoietic disorders; high-risk patients with risk of thromboembolism 4. Discontinuation of oral corticosteroids for less than 2 weeks; discontinuation of topical corticosteroids or oral antihistamines for less than 1 week 5. Patients under 18 years old or over 65 years old 6. Patients with skin lesions complicated by severe infection or other scalp skin diseases (such as psoriasis, tinea capitis, pityriasis amiantacea, lichen planus, systemic lupus erythematosus, etc.) 7. Alcohol abusers, drug abusers or drug-dependent individuals 8. Those who have participated in other clinical trials within the past month 9. Other conditions deemed inappropriate for participation by the researchers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total Effective Rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| TCM Syndrome Score;The Dermatology Life Quality Index ;Transepidermal Water Loss (TEWL);Stratum Corneum Moisture Content;Skin Sebum Content;Skin pH Value;Changes in Hair Follicles and Skin Images at Lesion Sites;microbiota samples from skin lesions and adjacent healthy skin; | — |
Countries
China
Contacts
Public ContactLiwei Wang
Skin and Cosmetic Research Department, Shanghai Dermatology Hospital
Outcome results
None listed